AstraZeneca stock analysis
AstraZeneca (ZEG) Stock Price & Analysis
ZEG Stock Chart & Stats
- Day’s Range
- CHF 152.76 - CHF 154.40
- 52-Week Range
- CHF 121.57 - CHF 160.00
- Previous Close
- CHF 153.54
- Volume
- N/A
- Average Volume (3M)
- 20
- Market Cap
- CHF 237.98B
- Enterprise Value
- CHF 211.22B
- Total Cash (Recent Filing)
- CHF 8.11B
- Total Debt (Recent Filing)
- CHF 33.97B
- Price to Earnings (P/E)
- 25.9
- Beta
- 0.30
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 1.91
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.75%
Bulls Say, Bears Say
Bulls Say
Broad Portfolio Growth
Growth across several major therapy areas and regions reduces reliance on any single medicine or market. This breadth supports more resilient revenue compounding, strengthens commercial scale, and provides a durable platform for absorbing weakness in mature products.
Deep Pipeline And Innovation
A large late-stage pipeline gives AstraZeneca multiple opportunities to replenish and expand its medicine portfolio as existing products mature. Repeated clinical and regulatory catalysts can extend growth, diversify future revenue, and reinforce its competitive position.
Strong Profitability And Balance Sheet
Improving margins and a growing equity base indicate substantial earnings power and financial resilience. Strong profitability can fund research, business development, and shareholder returns while helping the company support its broad innovation program over time.
Bears Say
Loss-of-exclusivity Pressure
Patent and biosimilar erosion is reducing revenue from important established medicines, creating a recurring replacement requirement for the pipeline. Continued generic competition can pressure growth and margins until newer launches become large enough to offset declines.
Mixed Cash Conversion
A meaningful gap between earnings and cash generation can constrain internally funded investment and shareholder returns if it persists. Lower operating cash flow despite higher earnings also increases reliance on working-capital normalization and disciplined cash management.
Restructuring And Investment Burden
Higher capital spending, deal-related payments, and restructuring costs will absorb cash while AstraZeneca continues investing heavily in research. Although intended benefits are substantial, execution over several years may pressure near-term margins and financial flexibility.
AstraZeneca News
AstraZeneca Advances New Ovarian Cancer Combination Study
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s TREVI-OC-02 study is testing torvutatug samrotecan with bevacizumab as first-line maintenance treatment for advanced ovarian, fallopian
AstraZeneca Advances China Cancer Trial as Durvalumab Takes Center Stage
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s Phase 3 MATTERHORN-CN study is testing treatment for Chinese patients with operable gastric and gastroesophageal junction
AstraZeneca Builds Hong Kong Breast Cancer Evidence in New Real-World Study
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s official study title is Breast Cancer Real-World Insights and Decision Guidance Evaluation (BRIDGE-HK) An Observational, Retrospective,
AstraZeneca Updates AZD4144 Drug-Interaction Study: What Investors Need to Know
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s NCT07685600 study, officially titled “An Open-label, Randomised, Two Arm, Fixed Sequence Study in Healthy Participants to
ZEG FAQ
What was AstraZeneca’s price range in the past 12 months?
What is AstraZeneca’s market cap?
When is AstraZeneca’s upcoming earnings report date?
How were AstraZeneca’s earnings last quarter?
Is AstraZeneca overvalued?
Does AstraZeneca pay dividends?
What is AstraZeneca’s EPS estimate?
How many shares outstanding does AstraZeneca have?
What happened to AstraZeneca’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AstraZeneca?
What is the TipRanks Smart Score and how is it calculated?
AstraZeneca Stock Smart Score
Company Description
AstraZeneca
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot
- Employees
- 96,100
- Website
- www.astrazeneca.com
- Address
- 1 Francis Crick Avenue, Cambridge, CA, CB2 0AA, GB
AstraZeneca (ZEG) Earnings & Revenues
ZEG Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. AstraZeneca reported solid revenue and EPS growth, broad-based commercial momentum, significant Phase III success, multiple new approvals and a deep pipeline with substantial 2027 catalysts. The company also reiterated full-year guidance and expressed confidence in growth through 2030 and beyond. Against this, the call included explicit challenges from loss of exclusivity, generic competition, VBP, lower operating cash flow, one clinical development discontinuation, higher investment and restructuring costs, and expected fourth-quarter expense pressures, but these were presented as manageable within the company's broader growth and pipeline strategy.
View all CH:ZEG earnings summariesZEG Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 4 |
| Technical Analysis | 2 | 4 | 3 |
| Moving Averages | 11 | 0 | 1 |
